Cytokinetics (CYTK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Backed by positive data from the SCOUT-HCM trial, the FDA has granted Priority Review to mavacamten (Camzyos) for adolescent oHCM.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results